Navigation Links
ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
Date:6/2/2011

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4. (ABSTRACT #4534)

In an exploratory, multi-institutional analysis, researchers administered the vaccine APC8015F to a group of patients from the control arm of three randomized, Phase 3 clinical trials evaluating sipuleucel-T, a similar, FDA-approved cancer vaccine for metastatic castrate resistant prostate cancer.

APC8015F is made from immune system cells taken from a patient with prostate cancer; however, unlike sipuleucel-T, which is never frozen, APC8015F is cryopreserved at a time before the disease progressed.

Results from the analysis showed that patients treated with APC8015F had improved survival relative to the patients who were not treated in the control arm. Following disease progression, the median survival of patients treated with APC8015F was 20.0 months compared to 9.8 months for control patients.

"The study is important because it suggests that the sipuleucel-T therapy may have extended survival for a longer time than estimated in the clinical trials due to the beneficial effects of the frozen product on some men who initially received the placebo," said Leonard Gomella, M.D., Chair of Urology at Jefferson's Kimmel Cancer Center in Philadelphia. "Further, the clinical activity of the frozen-activated product is maintained."

Post-progression treatment with APC8015F, which is not FDA approved, may have extended survival of subjects, potentially reducing the magnitude of survival difference observed between sipuleucel-T and controls in randomized controlled trials.

Sipuleucel-T is FDA approved under the brand name Provenge to treat men with advanced prostate cancer that is asymptomatic or minimally symptomatic and no longer responding to hormonal therapy.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-512-1783
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. ASCO: Glioblastoma in the 21st century: Wealthier patients living longer than poorer patients
2. ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer
3. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
4. Experimental treatment offers relief from painful prostate condition
5. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
6. Experimental Test May Warn of Premature Births
7. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
8. Experimental Weight-Loss Drug Seems to Work: Study
9. Experimental drug achieves unprecedented weight loss
10. Science at a glance: Symposia, research and special events at Experimental Biology 2011
11. A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney ... Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. ... to Highway 121. , As the practice has grown, the need for more space ...
(Date:2/24/2017)... ... 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... generation. Yisrayl makes an astounding statement when he says that the entire Bible ... Bible details the current times so plainly that anyone should be able to see ...
(Date:2/24/2017)... ... 24, 2017 , ... Rosica Communications, a national PR ... media relations, social media, content marketing and SEO, is now offering direct, social ... intuitive marketing automation platform. , Rosica will now offer the platform to its ...
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Australia , Feb. 23, 2017  Directors from Pharma To ... two companies have joined forces, resulting in the founding of Pharma ... Pharma To Market are pleased to announce their expansion ... office in Singapore . The company are delighted ... as Co-Director of the Singapore based entity. ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... -- LG Innotek hat heute die weltweit erste 70 mw ... 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C LED ... 280 nm und eignet sich damit für Sterilisationsaufgaben. Es verhindert ... Das Produkt von LG Innotek erzeugt UV-Strahlung im Bereich ... ...
Breaking Medicine Technology: